Gan & Lee Pharmaceuticals
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
通州区漷 8 县, Beijing, ChinaPhone Number
+86 1056965000Website
www.ganlee.comRevenue
$8.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals is a global pharmaceutical company dedicated to improving human health by delivering high-quality medicines and services. The company focuses on innovation and commercialization in areas such as diabetes, oncology, and medical devices. With a presence in 23 countries and a commitment to global business development, Gan & Lee aims to expand its impact worldwide. Their intended clients include patients and healthcare professionals seeking effective treatment options.Explore more
Gan & Lee Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gan & Lee Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Gan & Lee Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Gan & Lee Pharmaceuticals launches new products
Check out if Gan & Lee Pharmaceuticals is spiking on competitors!
Click to see if Gan & Lee Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Gan & Lee Pharmaceuticals has new funding data
Check if Gan & Lee Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Gan & Lee Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gan & Lee Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals financials insights
Gather financial insights about Gan & Lee Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$363.8M
Gan & Lee Pharmaceuticals Tech Stack
A closer look at the technologies used by Gan & Lee Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Hiring Plans
Gan & Lee Pharmaceuticals has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: JazzHR. Areas of expertise include: Regulatory Affairs Certification (RAC), Regulatory CMC, Regulatory Filings, Regulatory Compliance, and Regulatory Developments.
Hiring Plans
Open Position
Open Position
Gan & Lee Pharmaceuticals News & Media
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results....Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.Gan & Lee begins Phase III GLP-1 RA clinical trial in China
The GRADUAL clinical development programme comprises three Phase III studies, targeting over 1,000 subjects in China.Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gan & Lee Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Gan & Lee Pharmaceuticals is a global pharmaceutical company dedicated to improving human health by delivering high-quality medicines and services. The company focuses on innovation and commercialization in areas such as diabetes, oncology, and medical devices. With a presence in 23 countries and a commitment to global business development, Gan & L... Read More
